You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Adhesive Bond Strength of Bonded Structures in Confined Locations
SBC: LSP Technologies, Inc. Topic: SB123001Aerospace manufacturers are using composite structures in aircraft and they are the future of aviation. Composites reduce weight and maintenance costs. Today, many composite structures are joined together with fasteners. However to meet future design r
SBIR Phase II 2014 Department of DefenseDefense Advanced Research Projects Agency -
Superconducting Nanowire Single-Photon Detectors
SBC: Active Optoelectronics Topic: SB141001Our objective is to design and build a compact system that provides turnkey readiness for commercial and defense use of SNSPDs. Conventional SNSPDs face several limits that lead to tradeoffs between detection efficiency, bandwidth, dark count rate, jitter and operating temperature, and therefore prevent simultaneous realization of DARPA desired parameters in one device. We propose that amorphous N ...
SBIR Phase I 2014 Department of DefenseDefense Advanced Research Projects Agency -
Development of novel malaria parastie metabolite-based non-invasive diagnostic biosensor
SBC: GUILD ASSOCIATES INC Topic: N/AThe long term goal of the project is to use malaria parasite specific low-molecular-weight metabolites as biomarkers for development of sensitive, low-cost, simple, battery-operated field-deployable urine or saliva diagnostic biosensor for detection of malaria infection. Four malaria parasite-specific metabolites (3-Methylindole, Succinylacetone, S-Methyl-L-thiocitrulline, O-Arachidonoyl Glycidol ...
SBIR Phase I 2014 Department of Health and Human ServicesCenters for Disease Control and Prevention -
SBIR Phase II: Optimization of Rotavirus Vaccine Production
SBC: Meridian Life Sciences, Inc. Topic: N/ATo improve the safety and efficacy of oral rotavirus vaccines, CDC scientists have developed a proprietary inactivated rotavirus vaccine (IRV) technology (new human strains and a novel method for rotavirus inactivation) and demonstrated the immunogenicity in mice [14] and protective efficacy in piglets [15] of this IRV by intramuscular (IM) administration. More recently, CDC scientists have demons ...
SBIR Phase II 2014 Department of Health and Human ServicesCenters for Disease Control and Prevention -
Clear Cues: Supportive Wayfinding for Care Communities
SBC: Linda-&-Cameron, Inc. Topic: NIADESCRIPTION (provided by applicant): The purpose of this project is to develop and test Clear Cues (CC), a signage system for care communities that supports way finding in people with dementia. Way finding is a process through which people use informationin the environment to help them get to their desired destination. It's both the user experience of choosing a path and the design elements t ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Novel Alzheimer's Disease Drug Treatment
SBC: P2D, INC Topic: NIADESCRIPTION (provided by applicant): P2D Bioscience is developing the selective, non-addicting dopamine transport (DAT) inhibitor, PD2XXX, for the symptomatic treatment of Alzheimer's disease (AD). The core symptom of AD is short-term memory impairment. (DSM-IV) In preliminary studies, PD2XXX improved short term memory by over 110% in a well-accepted triple transgenic mouse model of AD (3xTg ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Targeted Inactivation of the CCR5 HIV Coreceptor with Peptide Nucleic Acids
SBC: L2 DIAGNOSTICS LLC Topic: NIAIDDESCRIPTION (provided by applicant): Over 34 million people are currently living with HIV/AIDS. Combination antiviral therapies have significantly reduced the morbidity and mortality of the disease; however, there is currently no cure for the disease. Discovery that a naturally occurring variant of CCR5, the delta32 mutation, renders cells resistant to HIV infection has led to efforts by several a ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Formulation of LbL microparticle vaccine in microneedle array for intradermal del
SBC: ARTIFICIAL CELL TECHNOLOGIES INC Topic: NIAIDAbstract The ability of the immune system to recognize and initiate an immune response to foreign particles such as bacteria and viruses has generated interest in development of particulate vaccine technologies. We are developing an innovative approach toproduce particulate vaccines via layer-by-layer (LbL) fabrication of synthetic microparticles (MP). We have shown that LbL-MP loaded with epitope ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
A novel antisense therapeutic for treatment of Aspergillus fumigatus infections
SBC: GUILD ASSOCIATES INC Topic: NIAIDDESCRIPTION (provided by applicant): Guild proposes to develop an antisense oligomer-based antifungal effective against the human pathogen Aspergillus fumigatus. With a 40%-60% mortality rate, invasive aspergillosis (IA) due to A. fumigatus now surpasses invasive candidiasis as the most frequent fungal cause of death, especially amongst immunocompromised patients. Successful therapy for IA with cu ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Targeting the Core Binding Factor tumor suppressor in MLL-fusion AML
SBC: P2D, INC Topic: NCIDESCRIPTION (provided by applicant): RUNX1 is considered a beneficial tumor suppressor in myeloid neoplasms. Inhibition of RUNX1 function has been implicated as an important mechanistic event in the development of core-binding factor-(CBF)-leukemia and MLL-fusion leukemia. Inactivating RUNX1 mutations are frequently found in patients with acute myeloid leukemia (AML). However, RUNX1 mutation is us ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health